

PCT/EP00/07904 which has an International filing date of August 14, 2000, which designated the United States of America.--

IN THE CLAIMS:

Please amend the claims as follows:

4. (Amended) Solid pharmaceutical preparation according to claim 1, characterized in that the active substance and the chitosan derivative are present in the nanosol in almost isoionic state.

5. (Amended) Solid pharmaceutical preparation according to claim 1, characterized in that the active substance is present in the nanosol in colloidal or in nanoparticulate form.

6. (Amended) Solid pharmaceutical preparation according to claim 1, characterized in that the active substance is poorly soluble.

7. (Amended) Solid pharmaceutical preparation according to claim 1, characterized in that it contains a further polymeric carrier substance apart from the chitosan derivative.

*A2  
cont*

8. (Amended) Use of a pharmaceutical preparation according to claim 1 for the production of a medicinal product.

10. (Amended) Use of a pharmaceutical preparation according to claim 8 for the production of a medicinal product that is administered as a powder, granulate, tablet or capsule.

11. (Amended) Use of a pharmaceutical preparation according to claim 8 for the production of a medicinal product which, for the purpose of administration, is dissolved or redispersed in a liquid.

*B3*

12. (Amended) Use of a pharmaceutical preparation according to claim 8 for the production of a medicinal product having controlled active substance release.

13. (Amended) Use of a pharmaceutical preparation according to claim 1 for the production of a diagnostic agent.

14. (Amended) Process for the production of a pharmaceutical preparation according to claim 1, characterized in that

a) a chitosan derivative is selected according to the type and relative number of its charged groups and in coordination with the type and relative number of the charged groups of the active substance such that at a certain pH value an isoionic state or

charge equalization between active substance and carrier can be achieved in the preparation,

- b) an aqueous sol containing the active substance is prepared from the chitosan derivative,
  - c) the pH value of the aqueous sol is adjusted such that an isoionic state results, possibly with colloidal or nano-scale active substance particles precipitating, and
  - d) the thus-adjusted aqueous sol is dried.